Skip to main content


  • Poster presentation
  • Open Access

EasypodTM adherence in children with growth disorders treated with r-hGH. A preliminary Italian experience

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9 and
  • 9
International Journal of Pediatric Endocrinology20132013 (Suppl 1) :P54

  • Published:


  • Growth Hormone
  • Short Stature
  • Human Growth
  • Human Growth Hormone
  • Daily Injection

Recombinant human growth hormone (r-hGH) is indicated for pediatric patients with a variety of growth disorders. Treatment with r-hGH requires long-term daily injections (1). Non-adherence or low adherence to treatment is associated with less favorable clinical outcomes, lower quality of life and higher healthcare costs (2,3). easypodTM has been specifically designed to improve patients’ ease of daily use and to minimize discomfort and pain (4,5).

Aim of this observational, national and multicentre study was to monitor the adherence to r-hGH treatment using easypodTM, which records time, date and dose of injections in patients with growth disorders during the 1st year of treatment.

98 pre-pubertal short stature patients with growth disorders (60 male and 37 female, 1 screening failure, median age 10 years) were enrolled in the study. So far data are available for 54 subjects. All subjects underwent a baseline visit, and then after 6 and 12 months. 8 patients were withdrawn from the study prematurely.

Data regarding r-hGH administration was uploaded from the autoinjectors. Auxological parameters, routine blood chemistry and hematology values were collected.

Adherence during the 1st year has been calculated. Adherence was defined as the proportion of injections correctly administered out of expected total number of injections during the observational period. A patient was considered as adherent if he/she correctly administered >92% of expected total number of injections during the observation period. Data on the 54 available patients show that 25 patients (46.3%) were adherent to treatment while 29 patients (53.7%) were not. The impact of low adherence on clinical and biochemical parameters is under evaluation.

The study will run until January 2013. Data obtained from this study will allow to explore the potential impact of adherence to r-hGH on growth outcomes after 1st year of treatment. The long-term adherence will be evaluated in the easypodTM connect observational study, also ongoing in Italy.

Authors’ Affiliations

Ospedale Microcitemico, Cagliari, Italy
Ospedale “Villa Sofia-Cervello”, Palermo, Italy
Università “Federico II”, Napoli, Italy
Istituto G. Gaslini, Genova, Italy
AORN Santobono – Pausillipon, Napoli, Italy
Presidio Ospedaliero “F. Ferrari” Casarano, Lecce, Italy
Polo Sanitario “Madre Teresa di Calcutta”, Potenza, Italy
Policlinico Universitario, Catania, Italy
Merck Serono S.p.A., Roma, Italy


© Loche et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.